Modern medicine saves lives but rarely restores them...until now.
At Oxia, we are uncovering how the body’s natural repair programs can be reactivated to reverse damage and rebuild tissue from within.
Our research focuses on Steroid Receptor Coactivators, or SRCs, which serve as the body’s master regulators of repair. These molecular conductors coordinate the genetic programs that protect, repair, and restore.
Through the development of Endogenous Repair Modulators , we are learning how to precisely activate these pathways so that cells can survive stress, limit inflammation, and recover function even under the most demanding conditions.
Oxia’s science represents a new frontier in medicine, one that uses the body’s own intelligence to heal from within.
"This could be the most important breakthrough in human healing...ever."
~ Dr. William Haseltine PhD, CoFounder Human Genome Sciences
Scientific Advisor, OXIA
Oxia's ERM Compound Amplifies Expression of SRC-Driven Cellular Repair Genes
Oxia’s lead ERM compound is a synthetic small molecule that activates SRC proteins, the cell’s master repair regulators, recruiting other co-activators to work in synergy. By acting on core biology, not a single disease pathway, our approach has broad potential across many conditions driven by cellular stress.
Oxia's ERM Compound Amplifies Expression of SRC-Driven Cellular Repair Genes
Oxia’s lead compound is a synthetic small molecule that activates SRC proteins, the key regulators of the body’s repair response.
.png)
Each result brings us closer to reimagining recovery. Our findings demonstrate that the body already contains the blueprint for healing and Oxia is mastering unlocking it. Oxia’s state-of-the-art research facility is built to accelerate these discoveries. Equipped with advanced molecular biology platforms, high-content imaging, and AI-driven analytics, it enables our scientists to study repair biology with unprecedented precision. Every experiment is designed to translate molecular insight into measurable impact with the goal of bridging the gap between discovery, medicine, and patient outcomes. In preclinical studies, our science has delivered remarkable results:
Up to 78% reduction in fibrosis
Preserves organ function after injury
Significant decreased tissue injury
Cells survive extreme hypoxia at 1% oxygen
Compelling Preclinical Lab Results
Our ERM platform is designed to activate SRCs precisely when and where they are needed. ERM therapies decrease tissue injury and preserve organ function. The addition of MI data strengthens our core thesis: the same repair biology that protects the kidney and brain also protects the heart. This cross-organ consistency underscores the breadth and scalability of Oxia’s ERM platform.
Stroke
Reduction in fibrosis & improvement in functional recovery
Kidney Injury
Treatment reduces kidney fibrosis in I/R model
Myocardial Infarction
Decreases Tissue Injury & Preserves Organ Function
